66th ASH Annual Meeting: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III

Symposia: Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products Oral and Poster Abstracts
Poster

Research, Lymphoid Leukemias, ALL, Fundamental Science, Clinical trials, Adult, Clinical Practice (Health Services and Quality), Lymphomas, Translational Research, Assays, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, Clinical Research, Blood banking, Diseases, Immune mechanism, Cell expansion, Treatment Considerations, Biological therapies, Immunology, Real-world evidence, Clinical procedures, Lymphoid Malignancies, Biological Processes, Myeloid Malignancies, Technology and Procedures, Gene editing, Study Population, Multi-systemic interactions, Human

Halls G-H (San Diego Convention Center)

4847

mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells Engineering for the Eradication of Leukemic Cells

Zhaozhao Chen, Doctor¹^*, Anqi Ren, Master^1,2^*, Jinhui Shu, Master³^*, Yingying Li^4,5^*, Hekuan Huang, Bachelor^2,3^*, Yu Hu^3,4^* and Heng Mei, Doctor¹^*

¹Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 中国, China
²Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
³Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China
⁴Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
⁵Hubei Clinical and Research Centre of Thrombosis and Haemostasis, Wuhan, China

4848

Evaluating Efficacy and Safety of Rapid-Manufactured CD5KO CART5 Cells in Preclinical Models of T Cell Malignancies

Ruchi P. Patel, PhD^1,2, Trang Vu, PhD²^*, Dean Qian, M.S.²^*, Yunlin Zhang, MS¹^*, Guido Ghilardi, MD¹^*, Steven Yang, M.D, Ph.D.²^*, Stefan K. Barta, MD³, Nicholas A. Siciliano, PhD²^*, Adam E. Snook, PhD^2,4^* and Marco Ruella, MD¹

¹Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
²Vittoria Biotherapeutics, Philadelphia, PA
³Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
⁴Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA

4849

Cord Blood-Derived Carcik Cells As Off-the-Shelf Non-Viral Cell Therapy for Hematological Malignancies

Ilaria Pisani¹^*, Giusi Melita¹^*, Simone Naso¹^*, Michele Francesco Quaroni²^*, Giada Matera²^*, Daniela Belotti²^*, Benedetta Cabiati²^*, Elisa Gotti³^*, Carolina Cuofano³^*, Chiara Capelli³^*, Jolanda Sarno¹^*, Angela Maria Savino⁴^*, Ilaria Ratti⁵^*, Daniele Prati⁵^*, Benedetta Rambaldi⁶^*, Giorgio Ottaviano⁷^*, Giovanna Lucchini⁷^*, Giuseppe Dastoli¹^*, Andrea Biondi^1,8, Alessandro Rambaldi⁹, Josee Golay³^*, Martino Introna³^*, Giuseppe Gaipa^1,2 and Sarah Tettamanti, PhD¹^*

¹Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
²Laboratorio di Terapia Cellulare e Genica Stefano Verri, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
³Centro di Terapia Cellulare "G. Lanzani", Bergamo, Italy
⁴Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy
⁵Department of Transfusion Medicine and Hematology, Milano Cord Blood Bank, Processing Facility and Biobank POLI-MI, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
⁶Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
⁷Department of Pediatrics, Bone Marrow Transplant Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
⁸Pediatrics Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
⁹Department of Oncology and Hematology, University of Milan and ASST Papa Giovanni XXIII, Bergamo, Italy

4850

Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

Gunjan L. Shah, MD^1,2,3, Karlo Perica, MD, PhD⁴, Katherine Nagel, NP⁵^*, Erica Payson⁵^*, Kinga K. Hosszu, PhD⁶^*, David J. Chung, MD, PhD^1,2,3, Heather J. Landau, MD^1,2,3, Michael Scordo, MD^1,2,3, Malin Hultcrantz, MD, PhD^3,7, Neha Korde, MD^3,8, Kylee H Maclachlan, PhD, BSc, FRACP, FRCPA^3,7, Urvi A. Shah, MD^3,7, Carlyn Rose Tan, MD^3,7, Hamza Sloan Hashmi, MD⁹^*, Alexander M. Lesokhin, MD^2,3,7, Sridevi Rajeeve, MD^2,3,7^*, Saad Z. Usmani, MD^1,2,3,8, Sham Mailankody, MD, MBBS^2,3 and Sergio A. Giralt, MD^1,2,3

¹Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Medicine, Weill Cornell Medical College, New York, NY
⁴Cellular Therapy Service, Memorial Sloan Kettering, New York, NY
⁵Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Department of Pediatrics, Immune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁹Myeloma Service, Department of Medicine, Memorial Sloan Kettering, Charleston, SC

4851

Novel Method to Evaluate the Quantitative Immune Functionality of CAR T-Cells to Analyze the Localization Change of CAR Molecules

Hiroshi Yasui, MD, PhD^1,2, Keiji Hirano³^*, Asako Kobayashi¹^*, Lihua Li, PhD¹^*, Takuya Takahashi³^*, Margarita Artemenko, MD, PhD³^*, Naotaka Noda, PhD³^*, Daichi Sadato, PhD⁴^*, Kyoko Haraguchi, MD, PhD⁵^*, Ayako Arai, MD, PhD², Kohzoh Imai, MD, PhD⁶^*, Noriko Doki⁷, Masatoshi Yanagida, PhD³^* and Tomohiro Ishigaki, MD, PhD⁸^*

¹The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
²Department of Hematology and Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
³Central Research Laboratories, Sysmex Corporation, Kobe, Japan
⁴Clinical Research and Trials Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
⁵Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyo-ku, Tokyo, Japan
⁶Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
⁷Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
⁸Department of Laboratory Medicine, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Minato-Ku, Tokyo, JPN

4852

Strategy to Improve Functional T-Cell Yield in Peripheral Blood By Co-Inhibition of Beta-2 Adrenergic and CXCR4 Signaling Pathways

Devki D. Sukhtankar, PhD^*, Thomas Cayton^*, Ashley Chin^*, Christian Ramos^*, Kanchan G Jhaver, Ph.D.^*, Nina Caculitan, PhD^* and Pina M. Cardarelli, Ph.D.

GPCR Therapeutics, Redwood City, CA

4853

Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

Alexandra Dreyzin, MD, MS^1,2^*, Yihua Cai, PhD¹^*, Kyu Lee Han, PhD¹^*, Michaela Prochazkova, PhD¹^*, Jennifer Webb, MD³, Keri Toner, MD³, Kathryn Bushnell, MS³^*, Bonnie Yates, NP²^*, Ping Jin, MD, MS¹^*, David F. Stroncek, MD, MS¹ and Nirali N. Shah, MD⁴

¹Center for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, MD
²Pediatric Oncology Branch, National Institutes of Health, Bethesda, MD
³Children's National Hospital, Washington, DC
⁴Pediatric Oncology Branch, NIH, Bethesda, MD

4854

Multiplexed Cytokine Assessment of T- and NK-Cell Responses to Tumor Cells: Parallel Assessment of Biomarkers Associated with Efficacy, Safety, and Persistence

Hans Layman¹^*, Belinda Jackson²^*, Natalya Belkina, PhD²^*, Sripriya Ranganathan, PhD²^* and Jacob N Wohlstadter²^*

¹Meso Scale Diagnostics, LLC, Pacifica, CA
²Meso Scale Diagnostics, LLC, Rockville, MD

4855

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Ao Zhang¹^*, Yingying Wu, MD²^*, Chunyan Sun³^*, Fang Liu¹^*, Tao Guo¹^*, Guohui Cui¹^*, Heng Mei¹^*, Jing He¹^*, Min Zhang¹^*, Chun Zhang¹^*, Qiuling Wu¹^*, Wenjun He¹^*, Zhipeng Chen¹^*, Fei Zhao³^*, Lin Liu¹^*, Bo Zhang¹^*, Lu Zhang¹^*, Danying Liao¹^*, Yu Hu³^*, Linghui Xia⁴^* and Jun Fang¹^*

¹Department of Haematology, Institute of Hematology, Union Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, China
²Department of Haematology, Institute of Hematology, Union Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, Hubei, China
³Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
⁴Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

4856

Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

Biping Deng, MS¹^*, Zhaoli Liu¹^*, Xiaoming Qu¹^*, Yu'e Zhang¹^*, Zhongxin Zhang¹^*, Rong Luan, phD¹^*, Lingli Zhang, MS¹^*, Ming Ma¹^*, Xiai Wu¹^*, Rui Liu²^*, Alex H. Chang³^*, Kai Hu, MD² and Chunrong Tong, MD⁴^*

¹Cytology Laboratory, Beijing GoBroad Boren Hospital, Beijing, China
²Department of Lymphoma and Myeloma Research Center, Beijing Gobroad Hospital, Beijing, China
³Shanghai YaKe Biotechnology Ltd, Shanghai, China
⁴Department of Hematology, Beijing GoBroad Boren Hospital, Beijing, China

4857

Analysis of Early Apheresis Immunophenotype, Batch Data Variables and Clinical Outcomes for Optimization of CAR-T-Cell Therapy in Aggressive B-Cell Lymphomas

Marcel Teichert¹^*, Keven Hörster, Dr. rer. nat.¹^*, Sarah Flossdorf²^*, Christine Hanoun¹^*, Ulrike Buttkereit, Dr. rer. medic.¹^*, Richard Noppeney, MD¹^*, Hans Christian Reinhardt, MD¹ and Bastian von Tresckow¹

¹Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
²Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University of Duisburg-Essen, Essen, Germany

4858

An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Nina Caculitan, PhD¹^*, GaYeon Kim²^*, Ann Woolfrey³^*, Luke P. Akard, MD⁴, Ah-Reum Jeong, MD⁵, Jack Khouri, MD⁶, Gunjan L. Shah, MD⁷ and Pina M. Cardarelli, Ph.D.¹

¹GPCR Therapeutics, Redwood City, CA
²GPCR Therapeutics, Inc., Seoul, Korea, Republic of (South)
³Medpace, Cincinnati, OH
⁴Indiana Blood and Marrow Transplantation, Franciscan Health, Indianapolis, IN
⁵UCSD Moores Cancer Center, La Jolla, CA
⁶Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁷Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH